Petosemtamab, with pembrolizumab, is in Phase III development for head and neck squamous cel and has two breakthrough therapy designations. The post Genmab to Acquire Merus and Novel Advanced Cancer Prospect for $8 Billion appeared first on Inside Precision Medicine.
